Madrigal Pharmaceuticals (MDGL) Return on Capital Employed (2011 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Return on Capital Employed of 34.63% for Q1 2026, up 1525.0% year-over-year from 2.13% in Q1 2025, and down 15.5% quarter-over-quarter from 29.99% in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Return on Capital Employed (2011 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 16 years of Return on Capital Employed data on file, last reported at 34.63% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 34.63%, up 1525.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 34.63% (up 1525.0% YoY), and the FY2025 annual result was 35.7%, up 3838.0% from the prior year.
- Return on Capital Employed retreated to 34.63% in Q1 2026 per MDGL's latest filing, from 29.99% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 29.99% in Q4 2025 and troughed at 307.99% in Q3 2022.
- A 5-year average of 109.88% and a median of 60.8% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed plunged 21186 bps in 2022, then jumped 14410 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 202.86% in 2022, then soared by 42 bps to 118.64% in 2023, then jumped by 53 bps to 56.04% in 2024, then soared by 46 bps to 29.99% in 2025, then slipped by 15 bps to 34.63% in 2026.
- Business Quant data shows MDGL's Return on Capital Employed at 34.63% in Q1 2026, 29.99% in Q4 2025, and 38.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | -34.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.63% |
| Dec 31, 2025 | -29.99% |
| Sep 30, 2025 | -38.56% |
| Jun 30, 2025 | -38.27% |
| Mar 31, 2025 | -49.89% |
| Dec 31, 2024 | -56.04% |
| Sep 30, 2024 | -60.31% |
| Jun 30, 2024 | -54.90% |
| Mar 31, 2024 | -60.80% |
| Dec 31, 2023 | -118.64% |
| Sep 30, 2023 | -204.41% |
| Jun 30, 2023 | -151.78% |
| Mar 31, 2023 | -126.15% |
| Dec 31, 2022 | -202.86% |
| Sep 30, 2022 | -307.99% |
| Jun 30, 2022 | -188.63% |
| Mar 31, 2022 | -144.19% |
| Dec 31, 2021 | -114.28% |
| Sep 30, 2021 | -96.13% |
| Jun 30, 2021 | -88.91% |